Oct 4- Atossa Genetics Inc said it would recall a medical device used to collect breast fluid for cancer detection along with a test that uses it, seven months after the U.S. Food and Drug Administration said the device needed additional clearance.» Read More
Intuitive Surgical is down about 18 percent today after pre-announcing a huge miss Monday, CNBC's Herb Greenberg brings everyone up to speed; and Jason Mills, analyst at Canaccord Genuity, explains why he downgraded the stock.
The delay of one of the key provisions of the Affordable Care Act has raised many questions. CNBC invited different analysts and experts to discuss the implications of the postponement.
Months before Americans buy coverage under Obamacare, it's becoming clear that choices for millions of people will vary depending on where they live. The NYT reports.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
With five months until 2014 open enrollment starts, the picture's a little clearer in some of the 16 states that are building their own health exchange marketplaces, with CNBC's Bertha Coombs.
Dr. Benjamin Carson was a political unknown just weeks ago. Now, He is in some ways a dream candidate for Republicans. The NYT reports.
Humana said the government's proposed 2014 payment rates for Medicare participants were lower than expected and would affect its profit outlook, and its shares fell in premarket trading.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.
The managing partner of Google's venture capital, Bill Maris, says under-investment in health sciences is short-sighted.
The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.
Qualcomm's CEO Paul Jacobs says the smart phone will become a focal point for wirelessly connecting medical devices, diagnostics and sensors, and providing near real-time information.
The aging of America is taking a toll on the health care system. By 2050, the cost of treating Alzheimer's patients will hit $1 trillion a year.
Despite piles of research on the skin cancer risks of sun exposure and tanning beds, dermatologists and cancer groups struggle to persuade people to protect their skin from ultraviolet rays.
With 12 million Americans allergic to one food item or another, sales of specialty foods are soaring.
It was a complicated case, in part because the reform legislation itself was seriously flawed. The law’s drafters could have proposed a simpler and more efficient system, the New York Times reports.
Expecting Aetna and UnitedHealth to beat Wall Street estimates as health insurers kick off fourth-quarter earnings, senior analyst Peter Costa of Wells Fargo says these companies will continue their winning streak in 2012, due to rising costs, lower unemployment and even health-care reform.
GNC is proving that health products may be recession-proof, with Joe Fortunato, chairman & CEO for GNC.
Is legislated healthcare reform here to stay? As we watch the presidential race heat up – and look to a Supreme Court ruling this summer — no one knows for sure. Regardless, we as a nation need to realize that traditional thinking around healthcare is forever changed.
The market is always too optimistic about firms under DOJ fraud investigation, says Sheryl Skolnick, CRT Capital healthcare analyst. Checking in on health care, with CNBC's Herb Greenberg.